Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm3 (ACTG 175)

被引:41
作者
Lathey, JL
Hughes, MD
Fiscus, SA
Pi, T
Jackson, JB
Rasheed, S
Elbeik, T
Reichman, R
Japour, A
D'Aquila, RT
Scott, W
Griffith, BP
Hammer, SM
Katzenstein, DA
机构
[1] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA
[2] Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA
[3] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA
[4] Stanford Univ, Dept Med, Palo Alto, CA 94304 USA
[5] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[6] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[7] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Beth Israel Deaconess Med Ctr,Div Infect Dis, Boston, MA 02114 USA
[8] London Sch Hyg & Trop Med, Med Stat Unit, London, England
[9] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
[10] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21224 USA
[11] Univ Rochester, Dept Pathol, Rochester, NY 14627 USA
[12] Univ Miami, Sch Med, Dept Pathol, Miami, FL 33101 USA
[13] Yale Univ, Dept Pathol, New Haven, CT 06520 USA
关键词
D O I
10.1086/514250
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Virologic measurements are increasingly used to evaluate prognosis and treatment responses in human immunodeficiency virus (HIV) type I infection. Markers of HIV-1 replication, including infectious HIV-1 titer from peripheral blood mononuclear cells, serum HIV-1 p24 antigen, plasma HIV-1 RNA, CD4 cell numbers, and viral syncytium-inducing (SI) phenotype, were determined in 391 virology substudy participants in AIDS Clinical Trials Group study 175. The subjects had 200-500 CD4 cells/mm(3), All markers of viral replication significantly correlated with one another and were inversely related to CD4 cell number. Disease progression to an AIDS-defining event or death or loss of >50% of CD4 cells was associated with infectious HIV-1 titer (P < .001), HIV-1 RNA (P < .001), and HIV-1 p24 antigen (P = .007). In multivariate proportional hazards models, p24 antigen was never significant when HIV-1 RNA level was included. In a model containing infectious HIV-1 titer (P = .038), HIV-1 RNA (P < .001), SI phenotype (P < .001), and CD4 cell number (P = .18), only the virologic parameters remained significantly associated with progression.
引用
收藏
页码:617 / 624
页数:8
相关论文
共 25 条
[1]  
BRAMBILLA DJ, 1996, 11 INT C AIDS VANC C, V11, P330
[2]   DECREASED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PLASMA VIREMIA DURING ANTIRETROVIRAL THERAPY REFLECTS DOWN-REGULATION OF VIRAL REPLICATION IN LYMPHOID-TISSUE [J].
COHEN, OJ ;
PANTALEO, G ;
HOLODNIY, M ;
SCHNITMAN, S ;
NIU, M ;
GRAZIOSI, C ;
PAVLAKIS, GN ;
LALEZARI, J ;
BARTLETT, JA ;
STEIGBIGEL, RT ;
COHN, J ;
NOVAK, R ;
MCMAHON, D ;
FAUCI, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (13) :6017-6021
[3]   Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection [J].
Coombs, RW ;
Welles, SL ;
Hooper, C ;
Reichelderfer, PS ;
DAquila, RT ;
Japour, AJ ;
Johnson, VA ;
Kuritzkes, DR ;
Richman, DD ;
Kwok, S ;
Todd, J ;
Jackson, JB ;
DeGruttola, V ;
Crumpacker, CS ;
Kahn, J .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (04) :704-712
[4]  
COOMBS RW, 1989, NEW ENGL J MED, V321, P1621
[5]   IMMUNODEFICIENCY VIRUS TYPE-1 QUANTITATIVE CELL MICROCULTURE AS A MEASURE OF ANTIVIRAL EFFICACY IN A MULTICENTER CLINICAL [J].
FISCUS, SA ;
DEGRUTTOLA, V ;
GUPTA, P ;
KATZENSTEIN, DA ;
MEYER, WA ;
LOFARO, ML ;
KATZMAN, M ;
RAGNI, MV ;
REICHELDERFER, PS ;
COOMBS, RW .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (02) :305-311
[6]   Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection [J].
GalettoLacour, A ;
Yerly, S ;
Perneger, TV ;
Baumberger, C ;
Hirschel, B ;
Perrin, L ;
Battegay, M ;
Burgisser, P ;
Doorly, R ;
Egger, M ;
Erb, P ;
Fierz, W ;
Flepp, M ;
Francioli, P ;
Grob, P ;
Gruninger, U ;
Ledergerber, B ;
Luthy, R ;
Malinverni, R ;
Matter, L ;
Opravil, M ;
Paccaud, F ;
Pichler, W ;
Rickenbach, M ;
Rutschmann, O ;
Vernazza, P ;
vonOverbeck, J .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (06) :1388-1393
[7]   USE OF VIROLOGICAL ASSAYS FOR DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS IN CLINICAL-TRIALS - RECOMMENDATIONS OF THE AIDS CLINICAL-TRIALS GROUP VIROLOGY COMMITTEE [J].
HAMMER, S ;
CRUMPACKER, C ;
DAQUILA, R ;
JACKSON, B ;
LATHEY, J ;
LIVNAT, D ;
REICHELDERFER, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (10) :2557-2564
[8]   A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter [J].
Hammer, SM ;
Katzenstein, DA ;
Hughes, MD ;
Gundacker, H ;
Schooley, RT ;
Haubrich, RH ;
Henry, WK ;
Lederman, MM ;
Phair, JP ;
Niu, M ;
Hirsch, MS ;
Merigan, TC ;
Blaschke, TF ;
Simpson, D ;
McLaren, C ;
Rooney, J ;
Salgo, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (15) :1081-1090
[9]   QUANTITATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 IN THE BLOOD OF INFECTED PERSONS [J].
HO, DD ;
MOUDGIL, T ;
ALAM, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (24) :1621-1625
[10]   Monitoring plasma HIV-1 RNA levels in addition to CD4(+) lymphocyte count improves assessment of antiretroviral therapeutic response [J].
Hughes, MD ;
Johnson, VA ;
Hirsch, MS ;
Bremer, JW ;
Elbeik, T ;
Erice, A ;
Kuritzkes, DR ;
Scott, WA ;
Spector, SA ;
Basgoz, N ;
Fischl, MA ;
DAquila, RT .
ANNALS OF INTERNAL MEDICINE, 1997, 126 (12) :929-938